BridgeMD
Compares treatment options for Diabetic Kidney Disease
Official title Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
ClinicalTrials.gov ID: NCT07169422
What this study is testing
- What it's testing
- Type 2 diabetes is the leading cause of chronic kidney disease, which can result in serious complications such as kidney failure and heart disease. Although effective medications exist to slow the progression of kidney damage, they are often underused in primary care, particularly for individuals without a regular family doctor.
- Time commitment: about 12 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml/min/1.73m2 and/or UACR≥3 mg/mmol)
- Adults who do not have primary care provider,
- Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA
You likely can't join if
- Hypotension
- Type 1 diabetes
- History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid...
- Already receiving all three medications: RASi, SGLT2i, and nsMRA .
- Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL/min/1.73m²
- Limited life expectancy of less than 1 year
See the full eligibility criteria
- Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml/min/1.73m2 and/or UACR≥3 mg/mmol)
- Adults who do not have primary care provider,
- Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA
- Hypotension
- Type 1 diabetes
- History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid receptor antagonist (nsMRA).
- Already receiving all three medications: RASi, SGLT2i, and nsMRA .
- Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL/min/1.73m²
- Limited life expectancy of less than 1 year
- Followed by a subspecialty physician (e.g., nephrologist or endocrinologist)
- Unable to give consent
The study team makes the final eligibility decision.
Where it's taking place
- Halifax, Nova Scotia, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Halifax, Nova Scotia, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.